1
|
Drysdale M, Galimov ER, Yarwood MJ, Patel V, Levick B, Gibbons DC, Watkins JD, Young S, Pierce BF, Lloyd EJ, Kerr W, Birch HJ, Kamalati T, Brett SJ. Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk COVID-19 patients in north west London: a retrospective cohort study. BMJ Open Respir Res 2024; 11:e002238. [PMID: 38575338 PMCID: PMC11002339 DOI: 10.1136/bmjresp-2023-002238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2023] [Accepted: 03/14/2024] [Indexed: 04/06/2024] Open
Abstract
BACKGROUND We assessed the effectiveness of sotrovimab vs no early COVID-19 treatment in highest-risk COVID-19 patients during Omicron predominance. METHODS Retrospective cohort study using the Discover dataset in North West London. Included patients were non-hospitalised, aged ≥12 years and met ≥1 National Health Service highest-risk criterion for sotrovimab treatment. We used Cox proportional hazards models to compare HRs of 28-day COVID-19-related hospitalisation/death between highest-risk sotrovimab-treated and untreated patients. Age, renal disease and Omicron subvariant subgroup analyses were performed. RESULTS We included 599 sotrovimab-treated patients and 5191 untreated patients. Compared with untreated patients, the risk of COVID-19 hospitalisation/death (HR 0.50, 95% CI 0.24, 1.06; p=0.07) and the risk of COVID-19 hospitalisation (HR 0.43, 95% CI 0.18, 1.00; p=0.051) were both lower in the sotrovimab-treated group; however, statistical significance was not reached. In the ≥65 years and renal disease subgroups, sotrovimab was associated with a significantly reduced risk of COVID-19 hospitalisation, by 89% (HR 0.11, 95% CI 0.02, 0.82; p=0.03) and 82% (HR 0.18, 95% CI 0.05, 0.62; p=0.007), respectively. CONCLUSIONS Risk of COVID-19 hospitalisation in sotrovimab-treated patients aged ≥65 years and with renal disease was significantly lower compared with untreated patients. Overall, risk of hospitalisation was also lower for sotrovimab-treated patients, but statistical significance was not reached.
Collapse
Affiliation(s)
| | | | | | | | - Bethany Levick
- Evidence & Access, OPEN Health Communications LLP, London, UK
| | | | | | | | | | | | - William Kerr
- Global Medical Affairs, GSK, Brentford, Middlesex, UK
| | | | | | - Stephen J Brett
- Department of Surgery and Cancer, Imperial College London, London, UK
| |
Collapse
|
2
|
Kitonsa J, Kamacooko O, Ruzagira E, Nambaziira F, Abaasa A, Serwanga J, Gombe B, Lunkuse J, Naluyinda H, Tukamwesiga N, Namata T, Kigozi A, Kafeero P, Basajja V, Joseph S, Pierce BF, Shattock R, Kaleebu P. A phase I COVID-19 vaccine trial among SARS-CoV-2 seronegative and seropositive individuals in Uganda utilizing a self-amplifying RNA vaccine platform: Screening and enrollment experiences. Hum Vaccin Immunother 2023; 19:2240690. [PMID: 37553178 PMCID: PMC10411305 DOI: 10.1080/21645515.2023.2240690] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Revised: 07/08/2023] [Accepted: 07/20/2023] [Indexed: 08/10/2023] Open
Abstract
We report the screening and enrollment process for a phase I vaccine trial in Masaka, Uganda that investigated the safety and immunogenicity of a self-amplifying SARS-CoV-2 RNA vaccine amongst individuals with and without antibodies to SARS-CoV-2. Participant screening and enrollment were conducted between December 2021 and April 2022. Individuals were eligible if they were aged between 18 and 45 years, healthy, and never vaccinated against COVID-19. SARS-CoV-2 antibody status was determined using two point-of-care rapid tests, i.e. Multi G (MGFT3) and Standard Q (Standard Q COVID-19 IgM/IgG Plus). Data were entered and managed in OpenClinica. Analyses were performed and presented descriptively. A total of 212 individuals were screened and 43(20.3%) enrolled. The most common reasons for exclusion were ≥ grade 1 laboratory abnormalities (39, 18.4%), followed by discordant SARS-CoV-2 antibody results (23, 10.9%). While the first 38 participants were quickly enrolled over a period of 9 weeks, it took another 9 weeks to enroll the remaining five, as antibody negative participants became scarce during the surge of the Omicron variant. The SARS-CoV-2 antibody positivity rate was determined to be 60.8% and 84.4% in each half of the 18 months of screening respectively. The mean age (±Standard Deviation, SD) of screened and enrolled participants was 27.7 (±8.1) and 30.2 (±8.3) years respectively. We demonstrated that it is feasible to successfully screen and enroll participants for COVID-19 vaccine trials in Uganda in the time of a pandemic. Our experiences may be useful for investigators planning to undertake similar work in Africa.
Collapse
Affiliation(s)
- Jonathan Kitonsa
- Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Onesmus Kamacooko
- Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Eugene Ruzagira
- Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Florence Nambaziira
- Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Andrew Abaasa
- Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
- Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
| | - Jennifer Serwanga
- Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Ben Gombe
- Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Jane Lunkuse
- Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Hadijah Naluyinda
- Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Naboth Tukamwesiga
- Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Tamara Namata
- Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Antony Kigozi
- Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Paddy Kafeero
- Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Vincent Basajja
- Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Sarah Joseph
- Department of Infectious Disease, Imperial College London, London, UK
| | | | - Robin Shattock
- Department of Infectious Disease, Imperial College London, London, UK
| | - Pontiano Kaleebu
- Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| |
Collapse
|
3
|
Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol 2021; 21:626-636. [PMID: 34373623 PMCID: PMC8351583 DOI: 10.1038/s41577-021-00592-1] [Citation(s) in RCA: 623] [Impact Index Per Article: 207.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/14/2021] [Indexed: 02/07/2023]
Abstract
Where 2020 saw the development and testing of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has seen vaccine rollout in many countries. In this Progress article, we provide a snapshot of ongoing vaccine efficacy studies, as well as real-world data on vaccine effectiveness and the impact of virus variants of concern. Where they have been deployed in a high proportion of the adult population, the currently approved vaccines have been extremely effective in preventing COVID-19, particularly severe disease. Nonetheless, there are still significant challenges in ensuring equitable vaccine access around the globe and lessons that can be learned for controlling this pandemic and for the next pandemic.
Collapse
Affiliation(s)
- John S Tregoning
- Department of Infectious Disease, St Mary's Campus, Imperial College London, London, UK.
| | - Katie E Flight
- Department of Infectious Disease, St Mary's Campus, Imperial College London, London, UK
| | - Sophie L Higham
- Department of Infectious Disease, St Mary's Campus, Imperial College London, London, UK
| | - Ziyin Wang
- Department of Infectious Disease, St Mary's Campus, Imperial College London, London, UK
| | - Benjamin F Pierce
- Department of Infectious Disease, St Mary's Campus, Imperial College London, London, UK
| |
Collapse
|
4
|
Kamacooko O, Kitonsa J, Bahemuka UM, Kibengo FM, Wajja A, Basajja V, Lumala A, Kakande A, Kafeero P, Ssemwanga E, Asaba R, Mugisha J, Pierce BF, Shattock RJ, Kaleebu P, Ruzagira E. Knowledge, Attitudes, and Practices Regarding COVID-19 among Healthcare Workers in Uganda: A Cross-Sectional Survey. Int J Environ Res Public Health 2021; 18:7004. [PMID: 34208959 PMCID: PMC8297128 DOI: 10.3390/ijerph18137004] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Revised: 06/23/2021] [Accepted: 06/24/2021] [Indexed: 01/12/2023]
Abstract
Healthcare workers (HCWs) are at high risk of COVID-19. However, data on HCWs' knowledge, attitudes, and practices (KAP) toward COVID-19 are limited. Between September and November 2020, we conducted a questionnaire-based COVID-19 KAP survey among HCWs at three hospitals in Uganda. We used Bloom's cut-off of ≥80% to determine sufficient knowledge, good attitude, and good practice, and multivariate Poisson regression with robust variance for statistical analysis. Of 717 HCWs invited to participate, 657 (91.6%) agreed and were enrolled. The mean age (standard deviation) of enrollees was 33.2 (10.2) years; most were clinical HCWs (64.7%) and had advanced secondary school/other higher-level education (57.8%). Overall, 83.9% had sufficient knowledge, 78.4% had a positive attitude, and 37.0% had good practices toward COVID-19. Factors associated with KAP were: Knowledge: being a clinical HCW (aRR: 1.12; 95% CI: 1.02-1.23) and previous participation in health research (aRR: 1.10; 95% CI: 1.04-1.17); Attitude: age > 35 years (aRR: 0.88; 95% CI: 0.79-0.98); Practice: being a clinical HCW (aRR: 1.91; 95% CI: 1.41-2.59). HCWs in Uganda have good knowledge and positive attitude but poor practices towards COVID-19. Differences in COVID-19 KAP between clinical and non-clinical HCWs could affect uptake of COVID-19 interventions including vaccination.
Collapse
Affiliation(s)
- Onesmus Kamacooko
- Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe P.O. Box 49, Uganda; (J.K.); (U.M.B.); (F.M.K.); (A.W.); (V.B.); (A.K.); (P.K.); (J.M.); (P.K.); (E.R.)
| | - Jonathan Kitonsa
- Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe P.O. Box 49, Uganda; (J.K.); (U.M.B.); (F.M.K.); (A.W.); (V.B.); (A.K.); (P.K.); (J.M.); (P.K.); (E.R.)
| | - Ubaldo M. Bahemuka
- Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe P.O. Box 49, Uganda; (J.K.); (U.M.B.); (F.M.K.); (A.W.); (V.B.); (A.K.); (P.K.); (J.M.); (P.K.); (E.R.)
| | - Freddie M. Kibengo
- Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe P.O. Box 49, Uganda; (J.K.); (U.M.B.); (F.M.K.); (A.W.); (V.B.); (A.K.); (P.K.); (J.M.); (P.K.); (E.R.)
| | - Anne Wajja
- Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe P.O. Box 49, Uganda; (J.K.); (U.M.B.); (F.M.K.); (A.W.); (V.B.); (A.K.); (P.K.); (J.M.); (P.K.); (E.R.)
| | - Vincent Basajja
- Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe P.O. Box 49, Uganda; (J.K.); (U.M.B.); (F.M.K.); (A.W.); (V.B.); (A.K.); (P.K.); (J.M.); (P.K.); (E.R.)
| | | | - Ayoub Kakande
- Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe P.O. Box 49, Uganda; (J.K.); (U.M.B.); (F.M.K.); (A.W.); (V.B.); (A.K.); (P.K.); (J.M.); (P.K.); (E.R.)
| | - Paddy Kafeero
- Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe P.O. Box 49, Uganda; (J.K.); (U.M.B.); (F.M.K.); (A.W.); (V.B.); (A.K.); (P.K.); (J.M.); (P.K.); (E.R.)
| | | | - Robert Asaba
- Our Lady of Consolata Kisubi Hospital, Entebbe P.O. Box 40, Uganda;
| | - Joseph Mugisha
- Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe P.O. Box 49, Uganda; (J.K.); (U.M.B.); (F.M.K.); (A.W.); (V.B.); (A.K.); (P.K.); (J.M.); (P.K.); (E.R.)
| | - Benjamin F. Pierce
- Department of Infectious Disease, Imperial College London, Norfolk Place, London W2 1PG, UK; (B.F.P.); (R.J.S.)
| | - Robin J. Shattock
- Department of Infectious Disease, Imperial College London, Norfolk Place, London W2 1PG, UK; (B.F.P.); (R.J.S.)
| | - Pontiano Kaleebu
- Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe P.O. Box 49, Uganda; (J.K.); (U.M.B.); (F.M.K.); (A.W.); (V.B.); (A.K.); (P.K.); (J.M.); (P.K.); (E.R.)
| | - Eugene Ruzagira
- Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe P.O. Box 49, Uganda; (J.K.); (U.M.B.); (F.M.K.); (A.W.); (V.B.); (A.K.); (P.K.); (J.M.); (P.K.); (E.R.)
| |
Collapse
|
5
|
Kitonsa J, Kamacooko O, Bahemuka UM, Kibengo F, Kakande A, Wajja A, Basajja V, Lumala A, Ssemwanga E, Asaba R, Mugisha J, Pierce BF, Shattock R, Kaleebu P, Ruzagira E. Willingness to participate in COVID-19 vaccine trials; a survey among a population of healthcare workers in Uganda. PLoS One 2021; 16:e0251992. [PMID: 34043693 PMCID: PMC8158909 DOI: 10.1371/journal.pone.0251992] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2021] [Accepted: 05/07/2021] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Healthcare workers (HCWs) are at high risk of acquiring SARS-CoV-2 and COVID-19 and may therefore be a suitable population for COVID-19 vaccine trials. We conducted a survey to evaluate willingness-to-participate in COVID-19 vaccine trials in a population of HCWs at three hospitals in Uganda. METHODS The survey was conducted between September and November 2020. Using a standardised questionnaire, data were collected on socio-demographics, previous participation in health research, COVID-19 information sources, underlying health conditions, and willingness-to-participate in COVID-19 vaccine trials. Data were analysed descriptively and a binomial generalised linear model with a log link function used to investigate factors associated with unwillingness to participate. RESULTS 657 HCWs (female, 63%) were enrolled with a mean age of 33 years (Standard Deviation, 10). Overall willingness-to-participate was 70.2%. Key motivating factors for participation were: hope of being protected against COVID-19 (81.1%), altruism (73.3%), and the opportunity to get health care (26.0%). Selected hypothetical trial attributes reduced willingness-to-participate as follows: weekly-quarterly study visits over a 12-month period (70.2%-63.2%, P = 0.026); provision of approximately 50ml of blood at each study visit (70.2%-63.2%, P = 0.026); risk of mild-moderate local adverse reactions (70.2%-60.3%, P<0.001); chance of receiving candidate vaccine or placebo (70.2%-56.9%, P<0.001); and delay of pregnancy [Overall, 70.2%-57.1% P<0.001); Female, 62.8%-48.4% (P = 0.002); Male, 82.5%-71.5% (P = 0.003)]. Collectively, these attributes reduced willingness-to-participate from [70.2%-42.2% (P<0.001) overall; 82.5%-58.1% (P<0.001) in men; 62.8%-32.6% (P<0.001) in women]. Among individuals that were unwilling to participate, the commonest barriers were concerns over vaccine safety (54.6%) and fear of catching SARS-CoV-2 (31.6%). Unwillingness to participate was associated with being female (aRR 1.97, CI 1.46-2.67, P<0.001) and having university or other higher-level education (aRR 1.52, CI 1.05-2.2, P = 0.026). CONCLUSIONS Willingness-to-participate in COVID-19 vaccine trials among HCWs in Uganda is high but may be affected by vaccine trial requirements and concerns about the safety of candidate vaccines.
Collapse
Affiliation(s)
- Jonathan Kitonsa
- Medical Research Council / Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Onesmus Kamacooko
- Medical Research Council / Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Ubaldo Mushabe Bahemuka
- Medical Research Council / Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Freddie Kibengo
- Medical Research Council / Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Ayoub Kakande
- Medical Research Council / Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Anne Wajja
- Medical Research Council / Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Vincent Basajja
- Medical Research Council / Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | | | | | - Robert Asaba
- Our Lady of Consolata Kisubi Hospital, Wakiso District, Uganda
| | - Joseph Mugisha
- Medical Research Council / Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Benjamin F. Pierce
- Department of Infectious Disease, Imperial College London, Norfolk Place, London, United Kingdom
| | - Robin Shattock
- Department of Infectious Disease, Imperial College London, Norfolk Place, London, United Kingdom
| | - Pontiano Kaleebu
- Medical Research Council / Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Eugene Ruzagira
- Medical Research Council / Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| |
Collapse
|
6
|
Autefage H, Allen F, Tang HM, Kallepitis C, Gentleman E, Reznikov N, Nitiputri K, Nommeots-Nomm A, O'Donnell MD, Lange C, Seidt BM, Kim TB, Solanki AK, Tallia F, Young G, Lee PD, Pierce BF, Wagermaier W, Fratzl P, Goodship A, Jones JR, Blunn G, Stevens MM. Multiscale analyses reveal native-like lamellar bone repair and near perfect bone-contact with porous strontium-loaded bioactive glass. Biomaterials 2019; 209:152-162. [PMID: 31048149 PMCID: PMC6527862 DOI: 10.1016/j.biomaterials.2019.03.035] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2018] [Revised: 03/08/2019] [Accepted: 03/22/2019] [Indexed: 02/07/2023]
Abstract
The efficient healing of critical-sized bone defects using synthetic biomaterial-based strategies is promising but remains challenging as it requires the development of biomaterials that combine a 3D porous architecture and a robust biological activity. Bioactive glasses (BGs) are attractive candidates as they stimulate a biological response that favors osteogenesis and vascularization, but amorphous 3D porous BGs are difficult to produce because conventional compositions crystallize during processing. Here, we rationally designed a porous, strontium-releasing, bioactive glass-based scaffold (pSrBG) whose composition was tailored to deliver strontium and whose properties were optimized to retain an amorphous phase, induce tissue infiltration and encourage bone formation. The hypothesis was that it would allow the repair of a critical-sized defect in an ovine model with newly-formed bone exhibiting physiological matrix composition and structural architecture. Histological and histomorphometric analyses combined with indentation testing showed pSrBG encouraged near perfect bone-to-material contact and the formation of well-organized lamellar bone. Analysis of bone quality by a combination of Raman spectral imaging, small-angle X-ray scattering, X-ray fluorescence and focused ion beam-scanning electron microscopy demonstrated that the repaired tissue was akin to that of normal, healthy bone, and incorporated small amounts of strontium in the newly formed bone mineral. These data show the potential of pSrBG to induce an efficient repair of critical-sized bone defects and establish the importance of thorough multi-scale characterization in assessing biomaterial outcomes in large animal models.
Collapse
Affiliation(s)
- H Autefage
- Department of Materials, Imperial College London, London, SW7 2AZ, United Kingdom; Department of Bioengineering, Imperial College London, London, SW7 2AZ, United Kingdom; Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, United Kingdom
| | - F Allen
- Institute of Orthopaedics and Musculoskeletal Science, University College London, London, WC1E 6BT, United Kingdom
| | - H M Tang
- Department of Materials, Imperial College London, London, SW7 2AZ, United Kingdom
| | - C Kallepitis
- Department of Materials, Imperial College London, London, SW7 2AZ, United Kingdom; Department of Bioengineering, Imperial College London, London, SW7 2AZ, United Kingdom; Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, United Kingdom
| | - E Gentleman
- Centre for Craniofacial and Regenerative Biology, King's College London, London, SE1 9RT, United Kingdom
| | - N Reznikov
- Department of Materials, Imperial College London, London, SW7 2AZ, United Kingdom; Department of Bioengineering, Imperial College London, London, SW7 2AZ, United Kingdom; Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, United Kingdom
| | - K Nitiputri
- Department of Materials, Imperial College London, London, SW7 2AZ, United Kingdom; Department of Bioengineering, Imperial College London, London, SW7 2AZ, United Kingdom; Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, United Kingdom
| | - A Nommeots-Nomm
- Department of Materials, Imperial College London, London, SW7 2AZ, United Kingdom
| | - M D O'Donnell
- Department of Materials, Imperial College London, London, SW7 2AZ, United Kingdom
| | - C Lange
- Max Planck Institute of Colloids and Interfaces, Department of Biomaterials, Research Campus Golm, Potsdam, Germany
| | - B M Seidt
- Max Planck Institute of Colloids and Interfaces, Department of Biomaterials, Research Campus Golm, Potsdam, Germany
| | - T B Kim
- Department of Materials, Imperial College London, London, SW7 2AZ, United Kingdom
| | - A K Solanki
- Department of Materials, Imperial College London, London, SW7 2AZ, United Kingdom; Department of Bioengineering, Imperial College London, London, SW7 2AZ, United Kingdom; Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, United Kingdom
| | - F Tallia
- Department of Materials, Imperial College London, London, SW7 2AZ, United Kingdom
| | - G Young
- Department of Materials, Imperial College London, London, SW7 2AZ, United Kingdom
| | - P D Lee
- Department of Materials, Imperial College London, London, SW7 2AZ, United Kingdom; Mechanical Engineering, University College London, Torrington Place, London, WC1E 7JE, United Kingdom
| | - B F Pierce
- Department of Materials, Imperial College London, London, SW7 2AZ, United Kingdom; Department of Bioengineering, Imperial College London, London, SW7 2AZ, United Kingdom; Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, United Kingdom
| | - W Wagermaier
- Max Planck Institute of Colloids and Interfaces, Department of Biomaterials, Research Campus Golm, Potsdam, Germany
| | - P Fratzl
- Max Planck Institute of Colloids and Interfaces, Department of Biomaterials, Research Campus Golm, Potsdam, Germany
| | - A Goodship
- Institute of Orthopaedics and Musculoskeletal Science, University College London, London, WC1E 6BT, United Kingdom
| | - J R Jones
- Department of Materials, Imperial College London, London, SW7 2AZ, United Kingdom
| | - G Blunn
- Institute of Orthopaedics and Musculoskeletal Science, University College London, London, WC1E 6BT, United Kingdom; School of Pharmacy and Biomedical Sciences, University of Portsmouth, PO1 2DT Portsmouth, United Kingdom.
| | - M M Stevens
- Department of Materials, Imperial College London, London, SW7 2AZ, United Kingdom; Department of Bioengineering, Imperial College London, London, SW7 2AZ, United Kingdom; Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, United Kingdom.
| |
Collapse
|
7
|
Federico S, Pierce BF, Piluso S, Wischke C, Lendlein A, Neffe AT. Design von Decorin-basierten Peptiden, die an Kollagen I binden, und ihr Potenzial als Adhäsionssequenzen in Biomaterialien. Angew Chem Int Ed Engl 2015. [DOI: 10.1002/ange.201505227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
8
|
Vukićević R, Neffe AT, Luetzow K, Pierce BF, Lendlein A. Conditional Ultrasound Sensitivity of Poly[(N
-isopropylacrylamide)-co
-(vinyl imidazole)] Microgels for Controlled Lipase Release. Macromol Rapid Commun 2015; 36:1891-1896. [DOI: 10.1002/marc.201500311] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2015] [Revised: 07/08/2015] [Indexed: 11/08/2022]
Affiliation(s)
- Radovan Vukićević
- Institute of Biomaterial Science; Helmholtz-Zentrum Geesthacht; Kantstraße 55 14513 Teltow Germany
| | - Axel T. Neffe
- Institute of Biomaterial Science; Helmholtz-Zentrum Geesthacht; Kantstraße 55 14513 Teltow Germany
- Berlin-Brandenburg Center for Regenerative Therapies; Kanststr. 55 14513 Teltow Germany
- Institute of Chemistry; University of Potsdam; Karl-Liebknecht-Straße 24-25 14476 Potsdam Germany
| | - Karola Luetzow
- Institute of Biomaterial Science; Helmholtz-Zentrum Geesthacht; Kantstraße 55 14513 Teltow Germany
| | - Benjamin F. Pierce
- Institute of Biomaterial Science; Helmholtz-Zentrum Geesthacht; Kantstraße 55 14513 Teltow Germany
- Berlin-Brandenburg Center for Regenerative Therapies; Kanststr. 55 14513 Teltow Germany
| | - Andreas Lendlein
- Institute of Biomaterial Science; Helmholtz-Zentrum Geesthacht; Kantstraße 55 14513 Teltow Germany
- Berlin-Brandenburg Center for Regenerative Therapies; Kanststr. 55 14513 Teltow Germany
- Institute of Chemistry; University of Potsdam; Karl-Liebknecht-Straße 24-25 14476 Potsdam Germany
| |
Collapse
|
9
|
Federico S, Pierce BF, Piluso S, Wischke C, Lendlein A, Neffe AT. Design of Decorin-Based Peptides That Bind to Collagen I and their Potential as Adhesion Moieties in Biomaterials. Angew Chem Int Ed Engl 2015. [PMID: 26216251 DOI: 10.1002/anie.201505227] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Mimicking the binding epitopes of protein-protein interactions by using small peptides is important for generating modular biomimetic systems. A strategy is described for the design of such bioactive peptides without accessible structural data for the targeted interaction, and the effect of incorporating such adhesion peptides in complex biomaterial systems is demonstrated. The highly repetitive structure of decorin was analyzed to identify peptides that are representative of the inner and outer surface, and it was shown that only peptides based on the inner surface of decorin bind to collagen. The peptide with the highest binding affinity for collagen I, LHERHLNNN, served to slow down the diffusion of a conjugated dye in a collagen gel, while its dimer could physically crosslink collagen, thereby enhancing the elastic modulus of the gel by one order of magnitude. These results show the potential of the identified peptides for the design of biomaterials for applications in regenerative medicine.
Collapse
Affiliation(s)
- Stefania Federico
- Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Helmholtz-Zentrum Geesthacht, Kantstrasse 55, 14513 Teltow (Germany).,Institute of Chemistry, University of Potsdam, 14476 Potsdam-Golm (Germany)
| | - Benjamin F Pierce
- Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Helmholtz-Zentrum Geesthacht, Kantstrasse 55, 14513 Teltow (Germany)
| | - Susanna Piluso
- Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Helmholtz-Zentrum Geesthacht, Kantstrasse 55, 14513 Teltow (Germany).,Institute of Chemistry, University of Potsdam, 14476 Potsdam-Golm (Germany)
| | - Christian Wischke
- Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Helmholtz-Zentrum Geesthacht, Kantstrasse 55, 14513 Teltow (Germany)
| | - Andreas Lendlein
- Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Helmholtz-Zentrum Geesthacht, Kantstrasse 55, 14513 Teltow (Germany).,Institute of Chemistry, University of Potsdam, 14476 Potsdam-Golm (Germany)
| | - Axel T Neffe
- Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Helmholtz-Zentrum Geesthacht, Kantstrasse 55, 14513 Teltow (Germany). .,Institute of Chemistry, University of Potsdam, 14476 Potsdam-Golm (Germany).
| |
Collapse
|
10
|
Neffe AT, Pierce BF, Tronci G, Ma N, Pittermann E, Gebauer T, Frank O, Schossig M, Xu X, Willie BM, Forner M, Ellinghaus A, Lienau J, Duda GN, Lendlein A. One step creation of multifunctional 3D architectured hydrogels inducing bone regeneration. Adv Mater 2015; 27:1738-1744. [PMID: 25601165 DOI: 10.1002/adma.201404787] [Citation(s) in RCA: 65] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/16/2014] [Revised: 12/15/2014] [Indexed: 06/04/2023]
Abstract
Structured hydrogels showing form stability and elastic properties individually tailorable on different length scales are accessible in a one-step process. They support cell adhesion and differentiation and display growing pore size during degradation. In vivo experiments demonstrate their efficacy in biomaterial-induced bone regeneration, not requiring addition of cells or growth factors.
Collapse
Affiliation(s)
- Axel T Neffe
- Institute of Biomaterial Science, Helmholtz-Zentrum Geesthacht, Kantstrasse 55, 14513, Teltow, Germany; Berlin-Brandenburg Center for Regenerative Therapies, Augustenburger Platz 1, 13533 Berlin and Kantstr. 55, 14513, Teltow, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Pierce BF, Pittermann E, Ma N, Gebauer T, Neffe AT, Hölscher M, Jung F, Lendlein A. Viability of Human Mesenchymal Stem Cells Seeded on Crosslinked Entropy-Elastic Gelatin-Based Hydrogels. Macromol Biosci 2015. [DOI: 10.1002/mabi.201500017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
12
|
Rijckaert B, Neffe AT, Roch T, Gebauer T, Pierce BF, Görs J, Smink JJ, Gossen M, Lendlein A, Leutz A. A High Content Screening Assay for Evaluation of Biomaterial-Mediated Cell Fusion Processes. ACTA ACUST UNITED AC 2014. [DOI: 10.1002/masy.201400147] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- Bart Rijckaert
- Institute of Biomaterial Science; Helmholtz-Zentrum Geesthacht; Kantstr. 55 14513 Teltow Germany
- Berlin-Brandenburg Center for Regenerative Therapies; Föhrer Str 15 13353 Berlin Germany
- Institute of Biochemistry and Biology; University of Potsdam; 14476 Potsdam-Golm Germany
| | - Axel T. Neffe
- Institute of Biomaterial Science; Helmholtz-Zentrum Geesthacht; Kantstr. 55 14513 Teltow Germany
- Institute of Chemistry; University of Potsdam; 14476 Potsdam-Golm Germany
| | - Toralf Roch
- Institute of Biomaterial Science; Helmholtz-Zentrum Geesthacht; Kantstr. 55 14513 Teltow Germany
| | - Tim Gebauer
- Institute of Biomaterial Science; Helmholtz-Zentrum Geesthacht; Kantstr. 55 14513 Teltow Germany
- Institute of Chemistry; University of Potsdam; 14476 Potsdam-Golm Germany
| | - Benjamin F. Pierce
- Institute of Biomaterial Science; Helmholtz-Zentrum Geesthacht; Kantstr. 55 14513 Teltow Germany
- Berlin-Brandenburg Center for Regenerative Therapies; Föhrer Str 15 13353 Berlin Germany
| | - Julia Görs
- Institute of Biomaterial Science; Helmholtz-Zentrum Geesthacht; Kantstr. 55 14513 Teltow Germany
- Berlin-Brandenburg Center for Regenerative Therapies; Föhrer Str 15 13353 Berlin Germany
- Institute of Biochemistry and Biology; University of Potsdam; 14476 Potsdam-Golm Germany
| | - Jeske J. Smink
- Berlin-Brandenburg Center for Regenerative Therapies; Föhrer Str 15 13353 Berlin Germany
- Max-Delbrueck-Center for Molecular Medicine; 13125 Berlin Germany
| | - Manfred Gossen
- Institute of Biomaterial Science; Helmholtz-Zentrum Geesthacht; Kantstr. 55 14513 Teltow Germany
- Berlin-Brandenburg Center for Regenerative Therapies; Föhrer Str 15 13353 Berlin Germany
| | - Andreas Lendlein
- Institute of Biomaterial Science; Helmholtz-Zentrum Geesthacht; Kantstr. 55 14513 Teltow Germany
- Berlin-Brandenburg Center for Regenerative Therapies; Föhrer Str 15 13353 Berlin Germany
- Institute of Biochemistry and Biology; University of Potsdam; 14476 Potsdam-Golm Germany
- Institute of Chemistry; University of Potsdam; 14476 Potsdam-Golm Germany
| | - Achim Leutz
- Institute of Biomaterial Science; Helmholtz-Zentrum Geesthacht; Kantstr. 55 14513 Teltow Germany
- Berlin-Brandenburg Center for Regenerative Therapies; Föhrer Str 15 13353 Berlin Germany
- Max-Delbrueck-Center for Molecular Medicine; 13125 Berlin Germany
- Humboldt-University Berlin; Institute for Biology; Berlin Germany
| |
Collapse
|
13
|
Neffe AT, Chua K, Luetzow K, Pierce BF, Lendlein A, Abell AD. Crosslinking of gelatin by ring opening metathesis under aqueous conditions-an exploratory study. POLYM ADVAN TECHNOL 2014. [DOI: 10.1002/pat.3359] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Affiliation(s)
- Axel T. Neffe
- Institute of Biomaterial Science; Helmholtz-Zentrum Geesthacht; Kantstrasse 55 14513 Teltow Germany
| | - Krystle Chua
- Institute of Biomaterial Science; Helmholtz-Zentrum Geesthacht; Kantstrasse 55 14513 Teltow Germany
- ARC Centre of Excellence for Nanoscale BioPhotonics and the School of Chemistry and Physics; The University of Adelaide; Adelaide South Australia 5005 Australia
| | - Karola Luetzow
- Institute of Biomaterial Science; Helmholtz-Zentrum Geesthacht; Kantstrasse 55 14513 Teltow Germany
| | - Benjamin F. Pierce
- Institute of Biomaterial Science; Helmholtz-Zentrum Geesthacht; Kantstrasse 55 14513 Teltow Germany
| | - Andreas Lendlein
- Institute of Biomaterial Science; Helmholtz-Zentrum Geesthacht; Kantstrasse 55 14513 Teltow Germany
| | - Andrew D. Abell
- ARC Centre of Excellence for Nanoscale BioPhotonics and the School of Chemistry and Physics; The University of Adelaide; Adelaide South Australia 5005 Australia
| |
Collapse
|
14
|
Lendlein A, Pierce BF, Ambrosio L, Grijpma D. Advanced functional polymers for medicine: multifunctional biomaterials. Acta Biomater 2012; 8:4199. [PMID: 23036946 DOI: 10.1016/j.actbio.2012.09.036] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2012] [Indexed: 10/27/2022]
|
15
|
Pierce BF, Pittermann E, Ma N, Gebauer T, Neffe AT, Hölscher M, Jung F, Lendlein A. Macromol. Biosci. 3/2012. Macromol Biosci 2012. [DOI: 10.1002/mabi.201290008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
16
|
Pierce BF, Pittermann E, Ma N, Gebauer T, Neffe AT, Hölscher M, Jung F, Lendlein A. Viability of Human Mesenchymal Stem Cells Seeded on Crosslinked Entropy-Elastic Gelatin-Based Hydrogels. Macromol Biosci 2012; 12:312-21. [DOI: 10.1002/mabi.201100237] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2011] [Revised: 09/01/2011] [Indexed: 12/21/2022]
|
17
|
Roch T, Pierce BF, Zaupa A, Jung F, Neffe AT, Lendlein A. Reducing the Endotoxin Burden of Desaminotyrosine- and Desaminotyrosyl Tyrosine-Functionalized Gelatin. ACTA ACUST UNITED AC 2011. [DOI: 10.1002/masy.201100048] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
18
|
Pierce BF, Tronci G, Rößle M, Neffe AT, Jung F, Lendlein A. Photocrosslinked Co-Networks from Glycidylmethacrylated Gelatin and Poly(ethylene glycol) Methacrylates. Macromol Biosci 2011; 12:484-93. [DOI: 10.1002/mabi.201100232] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2011] [Revised: 09/20/2011] [Indexed: 12/12/2022]
|
19
|
|
20
|
Zaupa A, Neffe AT, Pierce BF, Nöchel U, Lendlein A. Influence of tyrosine-derived moieties and drying conditions on the formation of helices in gelatin. Biomacromolecules 2010; 12:75-81. [PMID: 21141880 DOI: 10.1021/bm101029k] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The single and triple helical organization of protein chains strongly influences the mechanical properties of gelatin-based materials. A chemical method for obtaining different degrees of helical organization in gelatin is covalent functionalization, while a physical method for achieving the same goal is the variation of the drying conditions of gelatin solutions. Here we explored how the introduction of desaminotyrosine (DAT) and desaminotyrosyl tyrosine (DATT) linked to lysine residues of gelatin influenced the kinetics and thermodynamic equilibrium of the helicalization process of single and triple helices following different drying conditions. Drying at a temperature above the helix-to-coil transition temperature of gelatin (T > T(c), called v(short)) generally resulted in gelatins with relatively lower triple helical content (X(c,t) = 1-2%) than lower temperature drying (T < T(c), called v(long)) (X(c,t) = 8-10%), where the DAT(T) functional groups generally disrupted helix formation. While different helical contents affected the thermal transition temperatures only slightly, the mechanical properties were strongly affected for swollen hydrogels (E = 4-13 kPa for samples treated by v(long) and E = 120-700 kPa for samples treated by v(short)). This study shows that side group functionalization and different drying conditions are viable options to control the helicalization and macroscopic properties of gelatin-based materials.
Collapse
Affiliation(s)
- Alessandro Zaupa
- Center for Biomaterial Development and Berlin-Brandenburg Center for Regenerative Therapies, Helmholtz-Zentrum Geesthacht, Kantstrasse 55, 14513 Teltow, Germany
| | | | | | | | | |
Collapse
|
21
|
Affiliation(s)
- Benjamin F. Pierce
- Department of Chemistry, University of North Carolina at Chapel Hill, CB#3290, Caudill Hall, North Carolina 27599-3290
| | - Andrew H. Brown
- Department of Chemistry, University of North Carolina at Chapel Hill, CB#3290, Caudill Hall, North Carolina 27599-3290
| | - Valerie V. Sheares
- Department of Chemistry, University of North Carolina at Chapel Hill, CB#3290, Caudill Hall, North Carolina 27599-3290
| |
Collapse
|